S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
NASDAQ:ELOX

Eloxx Pharmaceuticals (ELOX) Stock Price, News & Analysis

$0.90
+0.05 (+5.88%)
(As of 03/27/2024 ET)
Today's Range
$0.85
$1.00
50-Day Range
$0.75
$1.18
52-Week Range
$0.40
$10.90
Volume
18,074 shs
Average Volume
9,154 shs
Market Capitalization
$2.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.00

Eloxx Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
6,011.1% Upside
$55.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.71mentions of Eloxx Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($7.91) to ($7.39) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.97 out of 5 stars

ELOX stock logo

About Eloxx Pharmaceuticals Stock (NASDAQ:ELOX)

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

ELOX Stock Price History

ELOX Stock News Headlines

Eloxx Pharmaceuticals (ELOX) to Release Earnings on Friday
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Eloxx Pharmaceuticals (NASDAQ:ELOX) Stock Price Down 1.2%
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Vertex Pharmaceuticals Inc.
Eloxx Pharmaceuticals, Inc. (ELOX)
Eloxx Pharmaceuticals Inc ELOX
Eloxx Pharmaceuticals prices $2M stock offering
Eloxx Pharmaceuticals Announces Registered Direct Offering - Quick Facts
See More Headlines
Receive ELOX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eloxx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/03/2023
Today
3/27/2024
Next Earnings (Estimated)
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ELOX
Employees
18
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$55.00
High Stock Price Target
$55.00
Low Stock Price Target
$55.00
Potential Upside/Downside
+6,011.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-36,060,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($4.92) per share

Miscellaneous

Free Float
2,508,000
Market Cap
$2.83 million
Optionable
Not Optionable
Beta
2.73
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

ELOX Stock Analysis - Frequently Asked Questions

Should I buy or sell Eloxx Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eloxx Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ELOX shares.
View ELOX analyst ratings
or view top-rated stocks.

What is Eloxx Pharmaceuticals' stock price target for 2024?

1 Wall Street research analysts have issued 1-year price targets for Eloxx Pharmaceuticals' shares. Their ELOX share price targets range from $55.00 to $55.00. On average, they anticipate the company's stock price to reach $55.00 in the next year. This suggests a possible upside of 6,011.1% from the stock's current price.
View analysts price targets for ELOX
or view top-rated stocks among Wall Street analysts.

How have ELOX shares performed in 2024?

Eloxx Pharmaceuticals' stock was trading at $1.20 at the beginning of 2024. Since then, ELOX stock has decreased by 25.0% and is now trading at $0.90.
View the best growth stocks for 2024 here
.

When is Eloxx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our ELOX earnings forecast
.

How were Eloxx Pharmaceuticals' earnings last quarter?

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) posted its quarterly earnings data on Monday, April, 3rd. The company reported ($2.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.97) by $0.05.

What is Greg Williams' approval rating as Eloxx Pharmaceuticals' CEO?

1 employees have rated Eloxx Pharmaceuticals Chief Executive Officer Greg Williams on Glassdoor.com. Greg Williams has an approval rating of 49% among the company's employees. This puts Greg Williams in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Eloxx Pharmaceuticals to a friend.

Who are Eloxx Pharmaceuticals' major shareholders?

Eloxx Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Daniel E Geffken, Pontifax Management 4 GP (20 and Rajesh B Parekh.
View institutional ownership trends
.

How do I buy shares of Eloxx Pharmaceuticals?

Shares of ELOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ELOX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners